RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

NCT07009860 · Active, not recruiting

Last updated 2026-08-27

This clinical trial is testing the drug pemvidutide in adults with alcohol-associated liver disease to see how it affects liver stiffness over 24 weeks.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 121 people

Who can join Ages 18–75 · all sexes

Timeline Started 2025-06 · est. completion 2027-09

Where 37 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT07009860 ↗

Description as written by the study sponsor.

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD.

Treatments tested

Pemvidutide Drug

Pemvidutide 2.4 mg SC Injection
Placebo Other

Placebo SC Injection

Main thing measured	Relative (%) reduction in liver stiffness by VCTE compared to baseline
Sponsor	Altimmune, Inc.
Conditions studied	Alcohol-associated Liver Disease
GLP-1 drugs	pemvidutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07009860 ↗